Merck & Co., Inc. (TSX:MRK)
31.07
-1.18 (-3.66%)
Oct 26, 2026, 3:53 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $16.61B USD in the quarter ending June 30, 2026, with 5.07% growth. This brings the company's total for the last twelve months to $66.57B, up 4.64% year-over-year. In the year 2025, Merck & Co. had annual revenue of $65.01B with 1.31% growth.
Revenue (ttm)
$66.57B
Revenue Growth
+4.64%
P/S Ratio
5.14
Revenue / Employee
$887.59K
Employees
75,000
Market Cap
486.34B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Merck & Co. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.01B | 843.00M | 1.31% |
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | -5.32B | -11.36% |
| Dec 31, 2019 | 46.84B | 4.55B | 10.75% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.20B |
| Extendicare | 1.98B |
| Curaleaf Holdings | 1.87B |
| Green Thumb Industries | 1.72B |
| WELL Health Technologies | 1.52B |
| Sienna Senior Living | 1.08B |
| Knight Therapeutics | 547.31M |
| DRI Healthcare Trust | 285.04M |
Merck & Co. News
- 12 hours ago - Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next - Investopedia
- 14 hours ago - Merck & Co. Transcript: Investor update - Transcripts
- 14 hours ago - Merck & Co. Slides: Investor update - Filings
- 14 hours ago - Merck & Co. Press release: Investor update - Filings
- 17 hours ago - Merck says Keytruda reduced risk of disease progression in endometrial cancer - TheFly
- 17 hours ago - Merck's therapy extends survival in hard-to-treat uterine cancer patients - Reuters
- 17 hours ago - Merck reports sac-TMT reduced risk of death by 32% in TroFuse-005 trial - TheFly
- 17 hours ago - Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire